The Persistence and rate of protective mechanisms of SARS COV-2 immunoglobulins among infected patients : a systematic review /
The Persistence and rate of protective mechanisms of SARS COV-2 immunoglobulins among infected patients : a systematic review /
Micah Faith Q. Alita, Donouven P. Brondial, Patricia Mae S. De Pedro, Angel Anne Delos Reyes, Azielin Mearrah P. Escueta, Rechelle Kaye C. Lantajo, Golda Marie E. Pare, Sophia Juliana P. Reyes, Jann Germaine D. Sario and Angela Louise C. Sinlao.
- Fairview, Quezon City: School of Medical Technology, FEU-NRMF, 2023.
- 121 pages: illustrations, tables; 28 cm.
Includes appendices and bibliographical references.
Abstract: Important issues about COVID-19 such as persistence of antibodies and their rate of protective mechanisms spawn the healthcare industry because cases of reinfections abound. The CDC (2022) claims that the precise duration of COVID-19 immunoglobulin persistence and its consequent protective mechanisms among the infected is yet to be known. While the knowledge of numerous communities regarding SARS-CoV-2 is rapidly increasing, the understanding of how antibody responses translate into protection against reinfection remains a significant challenge. Therefore, this systematic review aims to determine the persistence of SARS-CoV-2 immunoglobulins, in general, and its consequent rate of protective mechanisms in infected individuals. A systematic review was conducted. Articles were screened following the updated 2020 PRISMA guidelines. Consequently, the risk of bias in such articles was, assessed using the appropriate JBI checklist and the Cochrane RoB 2 tool. All in all, 94 studies were included. SARS-CoV-2 immunoglobulins were shown to persist for 6-12 months. Adults, particularly those who are female and of working age, were also found to be more vulnerable to reinfection. Reinfection among these people also revealed that disease severity did not advance to severe or critical levels, but remained mild. Reinfections of vaccinated and/or previously infected individuals did not progress to severe or critical conditions. This was attributed to the persistence of SARS-CoV-2 immunoglobulins in both the previously infected and vaccinated individuals which remained detectable 6-12 months after completion of COVID-19 vaccination doses, demonstrating that such antibodies serve their purpose and are effective in protecting people.
Thesis - School of Medical Technology
persistence of SARS-CoV-2 immunoglobulins
rate of reinfection
vaccinated individuals
previously infected individuals
MT 2023 0002
Includes appendices and bibliographical references.
Abstract: Important issues about COVID-19 such as persistence of antibodies and their rate of protective mechanisms spawn the healthcare industry because cases of reinfections abound. The CDC (2022) claims that the precise duration of COVID-19 immunoglobulin persistence and its consequent protective mechanisms among the infected is yet to be known. While the knowledge of numerous communities regarding SARS-CoV-2 is rapidly increasing, the understanding of how antibody responses translate into protection against reinfection remains a significant challenge. Therefore, this systematic review aims to determine the persistence of SARS-CoV-2 immunoglobulins, in general, and its consequent rate of protective mechanisms in infected individuals. A systematic review was conducted. Articles were screened following the updated 2020 PRISMA guidelines. Consequently, the risk of bias in such articles was, assessed using the appropriate JBI checklist and the Cochrane RoB 2 tool. All in all, 94 studies were included. SARS-CoV-2 immunoglobulins were shown to persist for 6-12 months. Adults, particularly those who are female and of working age, were also found to be more vulnerable to reinfection. Reinfection among these people also revealed that disease severity did not advance to severe or critical levels, but remained mild. Reinfections of vaccinated and/or previously infected individuals did not progress to severe or critical conditions. This was attributed to the persistence of SARS-CoV-2 immunoglobulins in both the previously infected and vaccinated individuals which remained detectable 6-12 months after completion of COVID-19 vaccination doses, demonstrating that such antibodies serve their purpose and are effective in protecting people.
Thesis - School of Medical Technology
persistence of SARS-CoV-2 immunoglobulins
rate of reinfection
vaccinated individuals
previously infected individuals
MT 2023 0002
